Community Practice Connections™: Comprehensive Key Advances in Biosimilars for Retinal Diseases " Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Speci

Target Audience
This educational activity is directed toward retinal and general ophthalmologists and other health care professionals involved in the treatment of patients with retinal diseases, such as optometrists, advanced practitioners, and nurses.

Program Overview
Regular intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors are a standard of care for retinal diseases such as neovascular age-related macular degeneration and diabetic retinopathy. However, frequent injections of these biologic therapies create an economic burden for the health care system and patients. Like in other specialties such as oncology and rheumatology, recent developments in biosimilars have the potential to reduce costs in the ophthalmology space.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a live satellite symposium presented at the ASRS Annual Meeting 2022, held in July. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of using biosimilars for managing retinal diseases, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives
Upon completion of this activity, participants should be better able to:
Review the regulatory requirements for agents that are approved as biosimilars for reference biologic agents
Evaluate clinical evidence for biosimilars compared with reference biologic agents as treatment for retinal diseases
Develop strategies to address concerns regarding the use of biosimilars in patients with retinal diseases